Psychopharmacology questions become more manageable when you separate receptor binding, receptor action, drug exposure and the patient's presentation. A receptor profile can suggest a mechanism, but it cannot predict every benefit or adverse effect on its own. MRCPsych Paper A requires those distinctions, especially when a plausible receptor explanation is being mistaken for a complete clinical answer.
This guide was checked on 27 September 2026 against current product information for aripiprazole, haloperidol, risperidone and olanzapine. Product information supports medicine-specific statements; the original response examples below are simplified teaching models, not measured drug-response curves or prescribing instructions.
Read a receptor profile before choosing an answer
Affinity concerns binding. Intrinsic activity concerns what a bound ligand does in a specified system. Occupancy concerns the proportion of receptors occupied under particular conditions. Potency and maximum effect are related but different concepts. Confusing them can make a superficially fluent explanation wrong.
A medicine with high affinity is not automatically a full agonist. A partial agonist is not simply a weak antagonist. A laboratory binding result does not itself establish how much clinical benefit a patient will experience, because exposure, tissue context, signalling and other targets also matter.
When reading a table, establish what its symbols mean. A plus sign may represent a broad affinity category rather than a measured clinical effect. Do not silently convert a qualitative receptor table into an exact ranking of sedation, metabolic risk or efficacy.
Compare agonism, antagonism and partial agonism
In a deliberately simplified single-receptor model, a full agonist can produce the model's maximum response, an antagonist binds without activating that response and a partial agonist has a lower maximum response in the same system. The clinical behaviour of a real medicine is more complex than the cartoon.
An original schematic is:
Response as exposure increases in one hypothetical system
Full agonist: rises towards the model's maximum
Partial agonist: rises towards a lower plateau
Antagonist alone: no agonist response in this simplified model
Now add a full agonist to the system. A partial agonist occupying the same receptors may reduce the response relative to the full agonist alone. That is why context matters: the same ligand cannot be understood solely through the everyday meaning of "stimulating" or "blocking".
The aripiprazole SmPC describes a proposed combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at 5-HT2A receptors. Preserve the distinction between that mechanistic account and proof that every clinical effect is explained by a single receptor.
Map dopamine effects to the relevant pathway
Dopaminergic effects have different implications across pathways. A therapeutic explanation involving psychotic symptoms should not be conflated with the motor consequences associated with nigrostriatal signalling or the endocrine consequences of altering dopamine's restraint on prolactin secretion. The haloperidol product information describes central D2 antagonism and relevant motor effects, while risperidone information explicitly addresses hyperprolactinaemia.
For an examination answer, name the presentation before the pathway. Is the stem describing rigidity, subjective restlessness, an endocrine symptom or a change in psychotic experiences? Different motor adverse effects also need distinguishing rather than being compressed into one undifferentiated label.
A useful reasoning sentence is: "The timing and symptom pattern suggest a treatment-related effect; this mechanism is plausible, but alternative causes and the actual exposure still require assessment." This avoids treating a receptor association as a diagnosis made without clinical context.
Compare histamine, muscarinic and adrenergic effects
Histamine H1, muscarinic and alpha-adrenergic activity can help explain patterns such as sedation, antimuscarinic symptoms and postural hypotension. However, the extent and clinical importance differ between medicines and patients. Metabolic effects, QT-related risk and serious idiosyncratic reactions cannot be fully reconstructed from a short receptor chart.
The source-linked table below describes selected distinctions as published in product information checked on 27 September 2026. It is not a complete medicine comparison or a recommendation to switch treatment.
| Medicine | Selected pharmacological distinction | Clinical question the profile helps raise |
|---|---|---|
| Haloperidol | Potent central D2 antagonism | Could a new motor presentation relate to dopamine blockade? |
| Aripiprazole | Partial-agonist and antagonist actions differ by receptor | Why is partial agonism not equivalent to absence of adverse effects? |
| Risperidone | Dopamine and serotonin antagonism with other receptor activity | Are prolactin-related symptoms or orthostatic effects relevant? |
| Olanzapine | Broad receptor activity, including histaminergic and muscarinic effects | How should sedation, antimuscarinic symptoms and metabolic concerns be assessed? |
A clinical safety decision needs the full contraindications, warnings, interactions and monitoring information. A table row is not a substitute for that review.
Six original adverse-effect cases
All cases are fictional educational examples created in September 2026. They illustrate reasoning and contain no clinical doses.
Case one: new rigidity and slowness. A patient develops these symptoms after a change in a dopamine-blocking medicine. Nigrostriatal effects are a plausible explanation. The rejected shortcut is to assume that every movement disorder in a person taking an antipsychotic is identical; the examination and time course still matter.
Case two: uncomfortable inner restlessness. Another patient repeatedly gets up and describes being unable to remain still after a treatment change. Consider akathisia rather than assuming that visible movement proves worsening agitation from the underlying illness. The aripiprazole SmPC includes akathisia among relevant adverse effects despite the medicine's partial-agonist mechanism.
Case three: prolactin-related symptoms. A patient taking risperidone reports a new endocrine symptom. The treatment is a plausible contributor, but pregnancy, endocrine disease and other causes must be considered as appropriate. The correct reasoning links the symptom and medicine while avoiding a diagnosis based solely on a drug name. Risperidone's product information supports symptom-led assessment of prolactin-related effects.
Case four: sleepiness and reduced daytime function. A person reports sedation after treatment begins. H1-related effects may contribute, but sleep deprivation, other sedating medicines, illness and exposure also matter. The useful next question concerns timing and co-exposures, not simply whether the receptor table contains a plus sign.
Case five: dizziness on standing. A patient has a postural symptom after a medication change. Adrenergic effects are relevant to consider, but dehydration, autonomic dysfunction and other medicines remain possible. A receptor-based hypothesis should lead to appropriate assessment of the symptom and observations rather than automatic treatment alteration.
Case six: constipation and new abdominal concern. A patient taking a medicine with antimuscarinic effects develops worsening bowel symptoms. The mechanism may be relevant, but potentially serious gastrointestinal deterioration needs clinical assessment rather than reassurance that constipation is "expected". The dedicated clozapine monitoring article addresses its specific gastrointestinal safety issues; do not generalise one medicine's management to every antipsychotic.
For each case, change one fact. If the symptom preceded treatment, the causal argument weakens. If a second interacting medicine was introduced, exposure becomes important. If the patient is acutely unwell, an adverse-effect explanation must not delay assessment of other urgent causes.
Keep interactions and pharmacokinetics separate from receptor theory
A medicine's receptor activity does not change simply because its plasma exposure rises, but the clinical consequences may change. Enzyme inhibition, induction, organ dysfunction, adherence and formulation can affect exposure. The current SmPC should be used for the particular medicine rather than inferring every interaction from a class label.
The dedicated psychotropic pharmacokinetics tutorial covers half-life, accumulation and CYP reasoning. Here, the important boundary is that a correct pharmacodynamic explanation can still be incomplete when the stem describes a pharmacokinetic change.
Build a misconception-focused revision record
Write the symptom, likely mechanism, supporting evidence, alternative explanation and fact that would change the answer. Include serious adverse effects that cannot be safely predicted from receptors alone. This keeps mechanism knowledge connected to clinical interpretation without pretending that a revision card is a prescribing protocol.
Per iatroX product information, September 2026, the Socratic Tutor starts with an attempted question and asks targeted follow-ups. A useful prompt is to explain why a partial agonist can have a different effect in different signalling contexts, or why a receptor profile cannot establish causation in the fictional case. The goal is a defensible explanation, not a longer list of receptor abbreviations.
Frequently asked questions
Does high receptor affinity mean high clinical efficacy?
No. Binding affinity, intrinsic activity, exposure and clinical outcomes are different quantities.
Is a partial agonist simply a weak antagonist?
No. It has agonist activity in a defined system but can reduce the response relative to a full agonist when competing for the same receptors.
Can I predict every adverse effect from a receptor table?
No. Medicine-specific safety information, pharmacokinetics, patient factors and effects not captured by the table also matter.